Study to Evaluate the Efficacy and Safety of CM310 in Subjects With IgG4-related Disease
NCT ID: NCT05728684
Last Updated: 2023-02-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
20 participants
INTERVENTIONAL
2023-02-28
2024-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of CM310 in Healthy Subjects
NCT06161090
Clinical Study of CM338 in the Treatment of Immunoglobulin A Nephropathy
NCT05775042
Study of CM313 in Subject With IgA Nephropathy
NCT06830395
Study to Evaluate the Effect of XmAb®5871 on Disease Activity in Patients With IgG4-Related Disease (RD)
NCT02725476
The Safety and Efficacy of S103 in the Treatment of Refractory Generalized Myasthenia Gravis
NCT06958939
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CM310
CM310, subcutaneous
CM310
CM310 Injection
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CM310
CM310 Injection
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* With IGG4-related disease.
Exclusion Criteria
* Treponema pallidum antibody positive in screening period.
* Active hepatitis in screening period.
* With a history of solid organ or cell transplantation within 6 months before screening.
* With other medical or non-medical conditions that are not suitable for the study by the investigator.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Beijing Friendship Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Liu Yanying
Deputy Director of Rheumatology Department
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
YYXSSC-IIT-002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.